哌罗匹隆与氟哌啶醇治疗精神分裂症对照研究

A control study of perospirone vs haloperidol in the treatment of schizophrenia

目的：探讨哌罗匹隆与氟哌啶醇治疗精神分裂症的疗效和安全性。方法将93例精神分裂症患者随机分为两组，研究组48例，口服哌罗匹隆治疗，对照组45例，口服氟哌啶醇治疗，观察8周。于治疗前后采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果治疗各时点研究组阳性与阴性症状量表总分及各因子分均较治疗前有显著下降（P＜0.01），对照组总分及阳性症状、精神病理因子分较治疗前有显著下降（P＜0.01），阴性症状因子分与治疗前比较差异无显著性（P＞0.05），研究组治疗各时点阴性症状因子分显著低于对照组（P＜0.01）。治疗8周末两组显效率、总有效率比较差异无显著性（P＞0.05）。研究组不良反应发生率较低，其中锥体外系反应、静坐不能、嗜睡不良反应发生率显著低于对照组（ P＜0.01）。结论哌罗匹隆与氟哌啶醇治疗精神分裂症患者总体疗效相当，但哌罗匹隆改善阴性症状效果显著优于氟哌啶醇，且安全性高，依从性好，有利于改善患者的认知功能。

Objective To explore the efficacy and safety of perospirone and haloperidol in the treatment of schizophrenia .Methods Ninety‐three schizophrenics were randomly assigned to research group （n=48） taking orally perospirone and control group （n=45） did haloperidol for 8 weeks .Efficacies were assessed with the Positive and Negative Syndrome Scale （PANSS） before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale （TESS） .Results The total and each factor score of the PANSS at each time‐point lowered more significantly compared with pretreatment in the research group （P〈0.01） ,so did total ,positive symptom and psychopathology score in control group （P〈0.01） ,pre‐and post‐treatment negative symptom score had no significant difference （P〉0.05） ,and negative symp‐tom scores at each time‐point were significantly lower in research than control group （P〈0.01） .At the end of the 8th week obvious and total effective rate had no significant group differences （P〉0.05） .In re‐search group the incidence of adverse reactions was low and that of extrapyramidal side effects ,akathisia and lethargy were significantly lower than in control group （P〈 0.01） .Conclusion Perospirone’s and haloperidol’s total efficacy are equivalent in schizophrnia ,but the former has an advantage in improving negative symptoms ,higher safety and better compliance and is favorable to the improvement of cognitive function .